BioPharm Videos

Five-year follow-up data from the Phase 3 Kimmtrak trial are providing new evidence that precision immunotherapy approaches can deliver durable benefits in metastatic uveal melanoma, a disease long considered resistant to immune-based treatments.

SENN Development CEO Dr. Johannes Eisenhut discusses how Basel’s expanding life sciences ecosystem supports biopharma innovation through research infrastructure and specialized talent growth.

Celltrion’s Dr. Juby Jacob-Nara discussed how subcutaneous infliximab may improve convenience, adherence, and sustained remission for patients with inflammatory bowel disease, while reducing reliance on infusion centers and supporting broader patient-centered treatment goals.

Subcutaneous infliximab may help improve treatment convenience, dosing consistency, and long-term adherence for patients with inflammatory bowel disease, according to discussions at DDW 2026. Clinicians highlighted the potential for self-administered infliximab to support sustained remission while reducing infusion-center burden and improving patient-centered care.

Cell therapy developers are prioritizing scalable manufacturing strategies alongside efficacy to support broader commercial deployment, notes Cellular Origins CEO Dr. Edwin Stone at the 2026 ASGCT Annual Meeting.

Multi-attribute LC–MS methods improve characterization of complex bioconjugates, supporting scalable and regulatory-ready biotherapeutic development, says Agilent Technologies’ Dr. Ganesh Bala, who spoke at the 2026 AAPS National Biotechnology Conference.

Hypoimmune cell engineering may enable scalable type 1 diabetes therapies without immunosuppression, advancing regenerative medicine approaches, according to Dr. Steve Harr, president and CEO of Sana Biotechnology.

In the second half of an interview at the close of INTERPHEX 2026, Avantor’s Jerry Keybl explains that digital integration and AI-driven analytics enable predictive bioprocess control and can thus improve consistency, scalability, and data-driven manufacturing decisions.

Consistent fluid management across scales supports efficient bioproduction and reduces risk during scale-up of complex therapeutic modalities, says Avantor’s Jerry Keybl at INTERPHEX 2026.

AI and automation may streamline cell and gene therapy manufacturing by reducing labor demands while improving efficiency and supporting scalable production, says Dr. Alan Smith of Charles River Laboratories.

Dr. Alan Smith of Charles River Laboratories explains why early manufacturing planning and scalable processes are critical to ensure successful commercialization of complex cell and gene therapies as part of his panel discussion at INTERPHEX 2026.

At PDA Week this year, industry leaders highlighted the shift to applied AI in bio/pharma manufacturing and quality and compliance, while focusing on real-world implementation, say Kate Malachowski, PhD, and Malav Parikh, the co-chairs of PDA Week 2026, as they share their insights from the event.

Recapping this year’s PDA Week, Kate Malachowski, PhD, and Malav Parikh, the co-chairs of PDA Week 2026, share their insights on how AI and knowledge management are shaping the future of bio/pharma quality.

In the final part of the interview, Franco Negron, CEO, Simtra BioPharma Solutions notes the question frequently heard from sponsors and predicts where the CDMO market is heading.

Explore how strategic partnerships are reshaping bioprocessing and biopharma drug development, from early process design to scalable biologics manufacturing, with Manisha P. Desai, PhD, senior vice president, Product Development, at Bristol Myers Squibb.

In the second part of the interview, Franco Negron, CEO, Simtra BioPharma Solutions discusses the decision between insourcing manufacturing or partnering with a CDMO.

Franco Negron, CEO, Simtra BioPharma Solutions touches on rising demand for biologics and high-potency therapies and how driving early, large-scale investment in injectable manufacturing capacity keeps pace with market growth.

In the final installment of an interview with Cardinal Health’s Anna Catalanotto, she discusses how leveraging real-world evidence and advanced value-based reimbursement models can optimize clinical adoption and long-term sustainability of CGTs.

In the second half of an interview with Lonza’s Carrie Mason, Mason discusses how cross-training scientists enables scale-up of AI-enabled bioprocessing.

Sebastian Lykke Skafte Andersen, Joanna Sadowska, PhD, and Neil Sheppard, D.Phil, go behind the headlines.

Lonza’s Michael De Marco emphasizes that early tox milestones strengthen investor confidence, support funding decisions, and reduce development risk for emerging biotechs.

AI, biomarkers, and novel oncology modalities are driving evolution in biopharma pipelines, according to Nmblr CEO Janice MacLennan.

Janice MacLennan, CEO of Nmblr, notes how AI is transforming biopharma R&D and market access, forcing teams to prove value beyond science and redesign work around human strengths.

In part two of an interview, Daniel Delubac, iOrganBio CEO, explains how digitized, in-vitro human biology models aim to improve preclinical drug testing.

AI-driven human cell models aim to replace animal testing and deliver more accurate, data-driven insights, says iOrganBio CEO Daniel Delubac ahead of the J.P. Morgan Healthcare Conference.

In Episode 31, industry veteran Deborah Dunsire goes behind the headlines to discuss the current state of innovation and evolving drug development landscape.

Digitalization is expected to reshape bioprocessing, supply chains, and quality systems for biopharma developers amid tariffs, geopolitics, and shifting capital flows, according to BioPlan Associates’ Eric Langer.

In the biopharma industry during 2025, quality, tariffs, MFN pricing, and strategic outsourcing deals drove innovation and investment.